News

Chaoran Ma, MD, PhD, assistant professor at University of Massachusetts Amherst, talked about the association between bowel movement frequency, the gut microbiome, and cognitive function in patients living with dementia.

The neurologist in the Danish Dementia Research Center at Rigshospitalet in Copenhagen, Denmark, discussed a cohort study that examined the association between opioid use and the risk of mortality in an older patient population living with dementia. [WATCH TIME: 5 minutes]

Change in phosphorylated tau231, the primary outcome, favored nicotinamide despite not reaching statistical significance.

With the recent approval of lecanemab (Leqembi; Eisai), NeurologyLive took a closer look at the Alzheimer pipeline, and the potential agents clinicians should keep an eye on in the coming years.

Using a cohort of more than 600 cognitively normal adults, the MIND diet failed to outperform a control diet of mild caloric restriction on several outcomes, including cognition and hippocampal volumes.

The professor in the department of internal medicine at RUSH Medical College talked about estimating the prevalence of Alzheimer disease to uncover the variability in disease prevalence at a micro-level and its implications for public health programs. [WATCH TIME: 5 minutes]

The associate professor of neurology at the Indiana University School of Medicine provided commentary on a study comparing traditional cognitive screening methods and the Linus Health Digital Clock and Recall test.

David Bates, PhD, chief executive officer and co-founder of Linus Health, provided insight on the transition of lecanemab to traditional approval, and how this decision impacts future care for Alzheimer disease.

In a cohort of nearly 800 frail adults and elderly patients with neuropsychiatric symptoms, pimavanserin showed similar rates of treatment-related adverse events and discontinuations because of TEAEs to placebo.

The clinical relevance of donanemab was demonstrated through a slowing of clinical decline, stability of clinical symptoms, lowered risk of advancement to next clinical stage, and lower risk of meaningful within-patient change.

The associate professor of neurology at the Indiana University School of Medicine provided insight on the distinguishable characteristics of certain cognitive screening tools and the advantages to each. [WATCH TIME: 3 minutes]

Tenecteplase, a genetically modified molecule of alteplase, had similar benefit and safety as alteplase, and was not modified by baseline occlusion site.

The director of research for internal medicine and geriatrics at Indiana University School of Medicine provided perspective on navigating challenges with newly approved treatments for Alzheimer disease, and using resources efficiently. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

A comparison between impaired scores on Digital Clock and Recall and impaired scores on Montreal Cognitive Assessment produced a 76% concordance.

According to diary data, caregiver's perceived reciprocity showed a substantial direct influence on the occurrence of behavioral symptoms on both the current day and the subsequent day for patients with Alzheimer disease and related dementias.

The postdoctoral fellow at the University of California San Diego discussed using CRISPR-based gene editing to alter the amyloid precursor protein gene in mice models with symptoms of Alzheimer disease. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the Alzheimer's Association.

After 4 years of treatment, more than 95% of infants on risdiplam maintained the ability to swallow, an aspect of everyday life that is commonly lost within 2 years in patients with SMA.

Neurology News Network for the week ending July 15, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 14, 2023.

Over a 12-week period, the safety profile of a subcutaneous formulation of ocrelizumab was consistent with its original intravenous formulation, along with comparable MRI activity in the brain.

Clinicians must be armed with fact-based information on all treatment options especially newer medications and technologies—good clinical care must be both patient-centric and knowledge-driven.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jill Farmer, DO, MPH. [LISTEN TIME: 28 minutes]

The National Multiple Sclerosis Society sponsored research fellow at Kessler Foundation talked about a research project that investigates the differences in brain structure and aging metrics among patients with multiple sclerosis from differing racial and ethnic backgrounds. [WATCH TIME: 5 minutes]

The AHEAD study will incorporate innovative features such as screening with biomarkers in blood, novel PET agents, sensitive cognitive outcome scales, dosing tailored to the level of amyloid in the brain, and recruitment approaches to ensure diverse representation.

The director of neurology and neuromuscular medicine at the Children’s Hospital of the King’s Daughters in Norfolk, Virginia, provided background on findings from the phase 4 RESPOND study, and the potential of combining therapeutic approaches in SMA. [WATCH TIME: 4 minutes]

While results of the study do not support the advancement of vatiquinone for the treatment of mitochondrial disease associated seizures, PTC Therapeutics continues to plan to advance the agent in Friedreich ataxia.

The director of the Neuroinformatics Program at the University of California, Irvine, discussed complexities with different machine learning algorithms in migraine research, including findings from the AMPP study. [WATCH TIME: 5 minutes]

The highest proportions of patients with severe ocular impairment at baseline showed greater improvements in symptom severity on ravulizumab in comparison with placebo after 26 weeks.